What is Horizant and what is it used for?
Horizant is a brand-name medication containing the active ingredient gabapentin enacarbil. It is prescribed for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia (PHN), a type of nerve pain that can occur after shingles [1].
When does Horizant go off patent?
The patent exclusivity for Horizant is a complex issue that can be influenced by various factors, including patent litigation and the potential for generic competition. Information on specific patent expiry dates and any ongoing challenges can be found through specialized resources like DrugPatentWatch.com [2].
Are there generic versions of Horizant available?
As of late 2023 and early 2024, there is not a fully approved generic version of Horizant available in the market that would directly compete with the brand-name drug for its specific indications [2].
How do generic drugs become available?
The process for generic drug availability typically involves the patent for the brand-name drug expiring or being successfully challenged. Once patent protection ends, other pharmaceutical companies can apply to the U.S. Food and Drug Administration (FDA) for approval to market generic versions. These generics must demonstrate bioequivalence to the brand-name drug, meaning they contain the same active ingredient, dosage form, strength, and route of administration, and perform the same in the body [3].
What are the implications of generic availability for patients?
The introduction of generic alternatives generally leads to lower medication costs for patients and healthcare systems. This increased accessibility can improve treatment adherence and overall public health outcomes.
What is gabapentin enacarbil?
Gabapentin enacarbil is a prodrug of gabapentin. This means that gabapentin enacarbil itself is not the active form in the body; it is converted into gabapentin after administration. This conversion allows for a different pharmacokinetic profile, potentially improving absorption and extending the duration of action compared to immediate-release gabapentin [1].
Are there other treatments for Restless Legs Syndrome (RLS)?
Yes, other treatments are available for RLS. These can include lifestyle modifications, iron supplements (if a deficiency is present), dopamine agonists (such as pramipexole and ropinirole), and alpha-2 adrenergic agonists (like clonidine). Horizant, with gabapentin enacarbil, offers an alternative treatment option for individuals whose RLS is not adequately controlled by other therapies [1].
Are there other treatments for Postherpetic Neuralgia (PHN)?
Treatment for PHN can include various classes of medications such as anticonvulsants (like gabapentin and pregabalin), tricyclic antidepressants, topical treatments (lidocaine, capsaicin), and other pain relievers. Horizant is one of the options prescribed for PHN [1].
What are the key differences between Horizant and immediate-release gabapentin?
Horizant (gabapentin enacarbil) is designed for extended-release and is taken once daily, typically in the late afternoon or evening, for RLS. Immediate-release gabapentin is usually taken multiple times a day. The prodrug nature of gabapentin enacarbil allows for improved absorption and a different dosing schedule compared to immediate-release gabapentin [1].
What are the risks associated with Horizant?
Common side effects of Horizant can include dizziness, fatigue, and somnolence. Serious risks, although rare, can include allergic reactions, suicidal thoughts or behavior, and changes in mood or behavior. Patients should discuss any concerns with their healthcare provider [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022177s007lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-drugs